What it's for (Indications)
- Cephazolin, a first-generation cephalosporin antibiotic, is primarily indicated for the treatment of a broad range of bacterial infections caused by susceptible microorganisms.
- Its therapeutic utility spans various body systems, including respiratory tract infections (e.
- g.
- , pneumonia, bronchitis), urinary tract infections, skin and soft tissue infections (e.
- g.
- , cellulitis, abscesses), bone and joint infections (e.
- g.
- , osteomyelitis, septic arthritis), and septicemia.
- It is particularly effective against Gram-positive bacteria such as *Staphylococcus aureus* (methicillin-susceptible strains), *Streptococcus pneumoniae*, and Group A beta-hemolytic streptococci.
- Additionally, cephazolin possesses activity against certain Gram-negative organisms, including *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*.
- A significant indication for cephazolin is surgical prophylaxis, where it is widely used to prevent postoperative infections across a variety of surgical procedures, including cardiovascular, orthopedic, and gastrointestinal surgeries.
- It may also be used in the treatment of endocarditis caused by susceptible staphylococci or streptococci.
- Definitive diagnosis and susceptibility testing are crucial before initiating cephazolin therapy to ensure appropriate antimicrobial coverage.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Cephazolin is administered via intravenous (IV) or intramuscular (IM) injection. For adult patients with moderate to severe infections, the typical dosage ranges from 500 mg to 1 gram every 6 to 8 hours. In cases of severe, life-threatening infections, doses may be increased to 1.5 grams every 6 hours, though the maximum recommended daily dose generally should not exceed 6 grams. For surgical prophylaxis, a standard regimen involves administering 1 gram intravenously approximately 30 to 60 minutes prior to the surgical incision. Depending on the type and duration of surgery and the patient's risk factors, additional doses of 0.5 to 1 gram may be administered every 6 to 8 hours for a duration not exceeding 24 hours post-surgery. Critical dosage adjustments are imperative for patients with impaired renal function; reduced doses or extended dosing intervals are necessary to prevent drug accumulation and potential systemic toxicity. Pediatric dosages are determined based on body weight and the severity of the infection, and must be precisely calculated by a qualified healthcare professional. |
Safety & Warnings
Common Side Effects
- Adverse reactions associated with cephazolin use can range from mild and transient to severe and potentially life-threatening.
- Common side effects often involve the gastrointestinal system, including nausea, vomiting, diarrhea, and abdominal cramps.
- Local reactions at the injection site are also frequently reported, such as pain, tenderness, induration, and phlebitis (inflammation of the vein) following intravenous administration.
- More serious, albeit less common, adverse effects include hypersensitivity reactions, which can manifest as various dermatological symptoms like skin rash, urticaria, and pruritus.
- Severe hypersensitivity reactions, such as anaphylaxis, angioedema, bronchospasm, and hypotension, are rare but constitute a medical emergency.
- Hematologic abnormalities, including eosinophilia, leukopenia, neutropenia, thrombocytopenia, and a positive Coombs' test, have been observed.
- Hepatic effects, such as transient elevations in liver enzymes (AST, ALT, alkaline phosphatase), may occur.
- Renal dysfunction, while rare, can be seen, especially with high doses or in patients with pre-existing renal impairment.
- Furthermore, *Clostridioides difficile*-associated diarrhea (CDAD) and central nervous system effects, such as seizures (particularly in patients with renal impairment receiving inappropriately high doses), are serious but infrequent complications.
Serious Warnings
- Black Box Warning: **Serious Warnings** While cephazolin does not carry an official FDA Black Box Warning, clinicians and patients must be acutely aware of several serious safety concerns that necessitate careful consideration and management during its use. Foremost among these are the potential for severe hypersensitivity reactions, including anaphylaxis. These reactions, which can be life-threatening, may occur even in patients without a prior history of penicillin or cephalosporin allergy, but the risk is significantly higher in those with a history of severe allergic reactions to any beta-lactam antibiotics. Immediate recognition and prompt medical intervention with appropriate supportive measures are critical if such reactions occur. Patients should be thoroughly questioned about prior allergic reactions before initiating therapy. Another significant concern is the potential for *Clostridioides difficile*-associated diarrhea (CDAD), which can range in severity from mild diarrhea to severe, potentially fatal pseudomembranous colitis. CDAD has been reported with nearly all antibacterial agents, including cephazolin, and can manifest during or even weeks after the cessation of antibiotic therapy. It is imperative to consider CDAD in the differential diagnosis for any patient presenting with diarrhea subsequent to antibiotic use. Appropriate diagnostic and therapeutic measures must be initiated without delay to prevent serious complications. Furthermore, in patients with profound renal impairment or those receiving inappropriately high doses of cephazolin without adequate dosage adjustment, there is a risk of central nervous system effects, including seizures. This risk underscores the critical importance of vigilant monitoring of renal function and precise dose titration in susceptible patient populations to prevent drug accumulation and neurotoxicity. These serious warnings emphasize the necessity for careful patient selection, meticulous monitoring, and prompt management of adverse events to ensure patient safety during cephazolin therapy.
- Cephazolin should be prescribed with extreme caution in patients with a documented history of hypersensitivity to penicillin or other beta-lactam antibiotics, given the established potential for cross-reactivity, which can lead to severe and life-threatening allergic reactions, including anaphylaxis.
- A thorough medical history regarding previous allergic reactions is essential before initiating therapy.
- Prolonged use of cephazolin, similar to other antibiotics, may disrupt the normal flora, leading to the overgrowth of non-susceptible organisms and the potential development of superinfections.
- Close monitoring for signs of new infections is therefore advised.
- *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including cephazolin, and its severity can range from mild diarrhea to fatal colitis.
- It is crucial to consider CDAD in any patient presenting with diarrhea during or after antibiotic use.
- Dosage adjustments are mandatory for patients with impaired renal function to prevent drug accumulation and potential toxicity, including central nervous system events such as seizures.
- Regular monitoring of renal function is recommended during extended courses of cephazolin therapy in patients with compromised kidney function.
- Patients should be advised to report any signs of allergic reactions, persistent diarrhea, or other unusual symptoms immediately.
How it Works (Mechanism of Action)
Cephazolin exerts its potent bactericidal effects by interfering with the synthesis of the bacterial cell wall, a critical structural component essential for bacterial survival. As a first-generation cephalosporin, it belongs to the beta-lactam class of antibiotics. Its primary mechanism of action involves the inhibition of peptidoglycan synthesis, which is a crucial step in the formation of the rigid bacterial cell wall. Cephazolin achieves this by binding to specific enzymes located on the inner membrane of the bacterial cell wall, known as penicillin-binding proteins (PBPs). These PBPs are responsible for catalyzing the transpeptidation reaction, which cross-links the peptidoglycan strands, thereby providing structural integrity to the cell wall. By binding to and inactivating these PBPs, cephazolin prevents the proper cross-linking of peptidoglycan chains, leading to a compromised, unstable, and osmotically fragile bacterial cell wall. This disruption ultimately results in bacterial cell lysis and death. The selective toxicity of cephazolin against bacteria is due to the presence of cell walls in bacteria, which are absent in human cells, making it an effective targeted antibacterial agent.